SUVEN PHARMACEUTICALS
|
|
BOM : 543064     NSE : SUVENPHAR     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Good [Stock is Cheap] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Feb 07,2023 |
Price(EOD): ₹ 488.60
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 12,439.76 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SUVEN PHARMACEUTICALS | -0.7% | -0.8% | -11.8% |
SUN PHARMACEUTICAL INDUSTRIES | -0.8% | -0.3% | 15.9% |
DIVIS LABORATORIES | -18.1% | -20% | -34.8% |
CIPLA | -0.1% | -4.2% | 8.1% |
DR REDDYS LABORATORIES | 2.1% | 4.1% | -0.5% |
TORRENT PHARMACEUTICALS | 0.1% | -0.9% | 13.9% |
ABBOTT INDIA | 1.3% | -6.2% | 29.7% |
ZYDUS LIFESCIENCES | 10.1% | 11.4% | 15.4% |
ALKEM LABORATORIES | 1.1% | 1.3% | -13.2% |
FUNDAMENTAL ANALYSIS OF SUVEN PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SUVEN PHARMACEUTICALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
32.82
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 378.99 Cr
[Latest Qtr - Dec2022 - Consolidated Results ] 8.14
P/B Calculated based on Book Value of Rs 1,527.18 Cr
[Latest Year - Mar2022 - Consolidated Results ] 9.32
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,334.82 Cr
[Latest Qtr - Dec2022 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-17% -31% -31% |
SHARE PRICE MOMENTUM OF SUVEN PHARMACEUTICALS
SUVEN PHARMACEUTICALS vs SENSEX
DEBT OF SUVEN PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.06 0.13 0.24 0.14 |
0.06 0.12 0.22 0.13 |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SUVEN PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SUVEN PHARMACEUTICALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
27.07% 46.87% 48.35% 49.5% |
-9.66% -21.14% -38.99% -32.7% |
QtrlyTrend |
0 | |
Latest Qtr: Dec2022 | ||
Quarterly Result Analysis → |
SUVEN PHARMACEUTICALS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 500 | -0.3% | -3.2% | -2.4% |
S&P BSE 400 MIDSMALLCAP | -0.3% | -2.7% | -3.1% |
S&P BSE ALLCAP | -0.4% | -3.3% | -2.6% |
S&P BSE MIDSMALLCAP | -0.5% | -3.2% | -4.6% |
S&P BSE 250 SMALLCAP | -0.8% | -3% | -6.9% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 | -0.2% | -3.2% | -2.6% |
NIFTY MID SMALL400 | -0.4% | -3% | -3.2% |
NIFTY500 MULTICAP 50:25:25 | -0.4% | -3.2% | -3.5% |
NIFTY SMALLCAP250 | -1.2% | -3.5% | -9% |
You may also like the below Video Courses
FAQ about SUVEN PHARMACEUTICALS
Is SUVEN PHARMACEUTICALS good for long term investment?
As on Feb 07,2023, the Fundamentals of SUVEN PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of SUVEN PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SUVEN PHARMACEUTICALS UnderValued or OverValued?
As on Feb 07,2023, SUVEN PHARMACEUTICALS is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SUVEN PHARMACEUTICALS ?
As on Feb 07,2023, the Intrinsic Value of SUVEN PHARMACEUTICALS is Rs. 705.40 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 585.26
Fair Value [Median EV / Sales Model] : Rs. 705.40
Fair Value [Median Price / Sales Model] : Rs. 705.71
Estimated Median Fair Value of SUVEN PHARMACEUTICALS : Rs. 705.40
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is SUVEN PHARMACEUTICALS trading at a Premium or Discount?
As on Feb 07,2023, SUVEN PHARMACEUTICALS is trading at a Discount of -31% based on the estimates of Median Intrinsic Value!